With the US healthcare system creaking under the strain of delivering affordable access to quality care – real-world evidence (RWE) and value-based agreements offer a shining light to pharma’s struggles.
However, with siloed databases, poor customer awareness of data’s value and lethargic adoption of new techniques, much work remains to be done. The costs and complexity of executing on RWE and value-based contracting strategies must reduce for these processes to become the everyday and bring the relief that the healthcare system so desperately needs.
Pharmaceutical Company Silver USD 2099.0
Pharmaceutical Company Gold USD 2399.0
Pharmaceutical Company Diamon USD 2999.0
Solution Provider Silver USD 2399.0
Solution Provider Gold USD 2699.0
Solution Provider Diamond USD 3299.0
Speakers: Martina Flammer, SVP, Customer Value, Boehringer Ingelheim , Christopher Boone, VP, Real World Data and Analytics, Pfizer, Zhen Su, SVP, Chief Medical Officer, North America, EMD Serono , Martin Marciniak, VP, U.S. Medical Affairs, Customer Engagement, Value, Evidence and Outcomes, GSK, Khair ElZarrad, Deputy Director, Office of Medical Policy, FDA , John Bardi, VP, Public Affairs & Digital Health Business Development, Otsuka , Patrick Loerch, Senior Director, Data Sciences (Information, Knowledge Utilization - iKU), Celgene, Amanda Bruno, Head of Value, Evidence and Access, Oncology, GSK, Dan Leonard, President, National Pharmaceutical Council, Harry Vargo, Director of Value Based Contracting and Manufacturer Trade Relations, Aetna
Time: on Wednesday November 07, 2018 at 9:00 am (ends Thursday November 08, 2018 at 4:00 pm)eyeforpharma Value Summit
Venue details: Sonesta Philadelphia Downtown Rittenhouse Square